RÉSUMÉ
We have previously shown that more prominent immune responses are induced to antigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholerae than to antigens expressed from single-copy genes on the V. cholerae chromosome. Here, we report the construction of a DeltaglnA derivative of V. cholerae vaccine strain Peru2. This mutant strain, Peru2DeltaglnA, is unable to grow on medium that does not contain glutamine; this growth deficiency is complemented by pKEK71-NotI, a plasmid containing a complete copy of the Salmonella typhimurium glnA gene, or by pTIC5, a derivative of pKEK71-NotI containing a 1. 8-kbp fragment that directs expression of CtxB with a 12-amino-acid epitope of the serine-rich Entamoeba histolytica protein fused to the amino terminus. Strain Peru2DeltaglnA(pTIC5) produced 10-fold more SREHP-12-CtxB in supernatants than did ETR3, a Peru2-derivative strain containing the same fragment inserted on the chromosome. To assess immune responses to antigens expressed by this balanced lethal system in vivo, we inoculated germfree mice on days 0, 14, 28, and 42 with Peru2DeltaglnA, Peru2DeltaglnA(pKEK71-NotI), Peru2(pTIC5), Peru2DeltaglnA(pTIC5), or ETR3. All V. cholerae strains were recoverable from stool for 8 to 12 days after primary inoculation, including Peru2DeltaglnA; strains containing plasmids continued to harbor pKEK71-NotI or pTIC5 for 8 to 10 days after primary inoculation. Animals were sacrificed on day 56, and serum, stool and biliary samples were analyzed for immune responses. Vibriocidal antibody responses, reflective of in vivo colonization, were equivalent in all groups of animals. However, specific anti-CtxB immune responses in serum (P = 0.05) and bile (P = 0. 001) were significantly higher in animals that received Peru2DeltaglnA(pTIC5) than in those that received ETR3, confirming the advantage of higher-level antigen expression in vivo. The development of this balanced lethal system thus permits construction and maintenance of vaccine and vector strains of V. cholerae that express high levels of immunogenic antigens from plasmid vectors without the need for antibiotic selection pressure.
Sujet(s)
Antigènes bactériens/génétique , Glutamate-ammonia ligase/génétique , Glutamate-ammonia ligase/immunologie , Plasmides/génétique , Vibrio cholerae/génétique , Vibrio cholerae/immunologie , Administration par voie orale , Animaux , Anticorps antibactériens/sang , Antigènes de protozoaire/génétique , Vaccins antibactériens/administration et posologie , Vaccins antibactériens/génétique , Vaccins antibactériens/immunologie , Entamoeba histolytica/génétique , Entamoeba histolytica/immunologie , Femelle , Expression des gènes , Gènes bactériens , Test de complémentation , Vecteurs génétiques , Axénie , Glutamine/déficit , Intestins/immunologie , Intestins/microbiologie , Souris , Mutation , Protéines recombinantes/génétique , Protéines recombinantes/immunologie , Salmonella typhimurium/génétique , Salmonella typhimurium/immunologie , Vaccins atténués/administration et posologie , Vaccins atténués/génétique , Vaccins atténués/immunologieRÉSUMÉ
Salmonella typhi Ty800, deleted for the Salmonella phoP/phoQ virulence regulon has been shown to be a safe and immunogenic single dose oral typhoid fever vaccine in volunteers. This promising vaccine strain was modified to constitutively express a heterologous protein of Gram negative bacterial origin, Helicobacter pylori urease subunits A and B, yielding S. typhi strain Ty1033. Seven volunteers received single oral doses of > or = 10(10) colony forming units of Ty1033; an eighth volunteer received two doses 3 months apart. Side effects were similar to those observed previously in volunteers who received the unmodified vector Ty800. All volunteers had strong mucosal immune responses to vaccination as measured by increases in IgA-secreting cells in peripheral blood directed against S. typhi antigens. Seven of eight volunteers had convincing seroconversion as measured by increases in serum IgG directed against S. typhi flagella and lipopolysaccharide antigens by ELISA. No volunteer had detectable mucosal or humoral immune responses to the urease antigen after immunization with single doses of Ty1033. A subset of three volunteers received an oral booster vaccination consisting of recombinant purified H. pylori urease A/B and E. coli heat labile toxin adjuvant 15 days after immunization with Ty1033. None of three had detectable humoral or mucosal immune responses to urease. Expression of a stable immunogenic protein in an appropriately attenuated S. typhi vector did not engender detectable mucosal or systemic antibody responses; additional work will be needed to define variables important for immunogenicity of heterologous antigens carried by live S. typhi vectors in humans.
Sujet(s)
Protéines bactériennes/génétique , Vaccins antibactériens/immunologie , Helicobacter pylori/immunologie , Salmonella typhi/immunologie , Urease/immunologie , Vaccins synthétiques/immunologie , Adulte , Antigènes bactériens/immunologie , Vaccins antibactériens/effets indésirables , Femelle , Helicobacter pylori/enzymologie , Humains , Immunité muqueuse , Immunoglobuline A/sang , Immunoglobuline G/sang , Mâle , Adulte d'âge moyenRÉSUMÉ
The phoP/phoQ virulence regulatory genes of Salmonella typhi Ty2 were deleted, and the resultant strain (Ty800) was tested as a live attenuated typhoid fever vaccine in human volunteers. Groups of 2 or 3 subjects received single oral doses of 10(7), 10(8), 10(9), or 10(10) cfu. Two volunteers who received the largest dose had self-limited side effects; no bacteremias were detected. Ten of 11 subjects had evidence of intestinal immune responses to the vaccine as measured by increases in S. typhi lipopolysaccharide-specific IgA-secreting cells in peripheral blood samples. Humoral immune responses were measured and compared with those of control vaccinees who received 4 oral doses of S. typhi Ty21a. In the most sensitive assays, 9 of 11 volunteers and 5 of 8 Ty21a control vaccinees had evidence of IgG directed against S. typhi antigens. Ty800 is safe, and single oral doses are highly immunogenic in humans.
Sujet(s)
Anticorps antibactériens/sang , Salmonella typhi/immunologie , Vaccins antityphoparatyphoïdiques/administration et posologie , Adolescent , Adulte , Protéines bactériennes/génétique , ADN bactérien/analyse , Fèces/microbiologie , Femelle , Humains , Immunoglobuline A/sang , Immunoglobuline G/sang , Lipopolysaccharides , Mâle , Adulte d'âge moyen , Salmonella typhi/génétique , Salmonella typhi/isolement et purification , Délétion de séquence , Vaccins antityphoparatyphoïdiques/effets indésirables , Vaccins antityphoparatyphoïdiques/génétique , Vaccins antityphoparatyphoïdiques/immunologie , Vaccination , Vaccins atténués/administration et posologie , Vaccins atténués/effets indésirables , Vaccins atténués/immunologie , Vaccins synthétiques/administration et posologie , Vaccins synthétiques/effets indésirables , Vaccins synthétiques/immunologieRÉSUMÉ
Cholera vaccine candidate Peru-15 was derived from a Vibrio cholerae O1 El Tor Inaba strain by deleting the cholera toxin genetic element, introducing the gene encoding cholera toxin B subunit into recA, and screening for nonmotility. In a controlled study, Peru-15 (2 x 10(8) cfu) was administered to 11 volunteers. No vaccinee developed diarrhea, and 10 of 11 had > 4-fold rises in vibriocidal antibody titers. One month later, 5 vaccinees and 5 control volunteers were challenged with wild type V. cholerae O1. Four of 5 controls developed diarrhea (mean, 1.9 L). Two Peru-15 vaccinees developed diarrhea, 1 with < 0.3 L and 1 with approximately 1.0 L; this latter volunteer had not developed a significant vibriocidal immune response to vaccination. Peru-15 shows promise as a single-dose, oral cholera vaccine that is safe, immunogenic, and protective.
Sujet(s)
Vaccins anticholériques/administration et posologie , Vaccins anticholériques/usage thérapeutique , Choléra/prévention et contrôle , Administration par voie orale , Adolescent , Adulte , Anticorps antibactériens/sang , Vaccins anticholériques/effets indésirables , Diarrhée/prévention et contrôle , Humains , Sécurité , Résultat thérapeutique , Vaccins atténués/administration et posologie , Vaccins atténués/effets indésirables , Vaccins atténués/usage thérapeutique , Vaccins synthétiques/administration et posologie , Vaccins synthétiques/effets indésirables , Vaccins synthétiques/usage thérapeutiqueRÉSUMÉ
Live attenuated vector strains of Vibrio cholerae were derived from Peru-2, a Peruvian El Tor Inaba strain deleted for the cholera toxin genetic element and attRS1 sequences, which was developed as a live, oral vaccine strain. A promoterless gene encoding the Shiga-like toxin I B subunit (slt-IB) was inserted in the V. cholerae virulence gene irgA by in vivo marker exchange, such that slt-IB was under transcriptional control of the iron-regulated irgA promoter. slt-IB was also placed under transcriptional control of the V. cholerae heat shock promoter, htpGp, and introduced into either the irgA or lacZ locus, or both loci, on the chromosome of Peru-2, generating JRB10, JRB11, or JRB12, respectively. A new technique was used to perform allelic exchange with lacZ. This method uses plasmid p6891MCS, a pBR327 derivative containing cloned V. cholerae lacZ, to insert markers of interest into the V. cholerae chromosome. Recombinants can be detected by simple color screening and antibiotic selection. In vitro measurements of Slt-IB produced by the vector strains suggested that expression of Slt-IB from the irgA and htpG promoters was synergistic and that two copies of the gene for Slt-IB increased expression over a single copy. The V. cholerae vectors colonized the gastrointestinal mucosa of rabbits after oral immunization, as demonstrated by very high serum antibody responses to V. cholerae antigens. Comparison of the serologic responses to the B subunit of cholera toxin (CtxB) following orogastric inoculation either with the wild-type C6709 or with Peru-10, a strain containing ctxB regulated by htpGp, suggested that both the cholera toxin and heat shock promoters were active in vivo, provoking comparable immunologic responses. Orogastric inoculation of rabbits with vector strains evoked serum immunoglobulin G (IgG) responses to Slt-IB in two of the four strains tested; all four strains produced biliary IgA responses. No correlation was observed between the type of promoter expressing slt-IB and the level of serum IgG or biliary IgA response, but the vector strain containing two copies of the gene for slt-IB evoked greater serum IgG responses than strains containing a single copy, consistent with the increased expression of Slt-IB from this strain observed in vitro. A comparison of the serum and biliary antibody responses to Slt-IB expressed from htpGp versus CtxB expressed from the same promoter suggested that CtxB is a more effective orally delivered immunogen.
Sujet(s)
Antigènes bactériens/génétique , Régulation de l'expression des gènes bactériens , Protéines recombinantes/métabolisme , Vaccins atténués/génétique , Vaccins synthétiques/génétique , Vibrio cholerae/génétique , Administration par voie orale , Animaux , Animaux allaités , Anticorps antibactériens/biosynthèse , Toxines bactériennes/génétique , Séquence nucléotidique , Bile/immunologie , Gènes bactériens , Vecteurs génétiques/génétique , Immunoglobuline A/biosynthèse , Immunoglobuline G/biosynthèse , Opéron lac , Souris , Lignées consanguines de souris , Données de séquences moléculaires , Sondes oligonucléotidiques/composition chimique , Régions promotrices (génétique) , Lapins , Shiga-toxine-1 , Vibrio cholerae/immunologieRÉSUMÉ
New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and AI4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16. A stable spontaneous non-motile derivative of Bengal-3 was isolated and designated Bengal-15; VRI-16 is naturally non-motile. Bengal-3, Bengal-15, and VRI-16 were evaluated as oral single-dose cholera vaccine candidates in 4 volunteers each, and MO10 was given to 3 volunteers. 1 of 4 volunteers who received Bengal-3 and all 3 who received MO10 had diarrhoea. VRI-16 caused no significant symptoms but was not immunogenic. Bengal-15 produced few symptoms and was nearly as immunogenic as MO10. Subsequently, Bengal-15 was given to 10 volunteers at a dose of 10(8) colony-forming units. No volunteers had diarrhoea, and other subjective symptoms were as common in vaccinees as in 3 buffer recipients. 1 month after vaccination, 7 vaccinees, the 3 buffer recipients, and 3 unimmunised subjects were challenged with 5 x 10(6) colony-forming units of V cholerae O139. 5 of 6 controls had cholera-like diarrhoea. By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.
Sujet(s)
Vaccins anticholériques , Administration par voie orale , Adolescent , Adulte , Anticorps antibactériens/sang , Choléra/prévention et contrôle , Vaccins anticholériques/administration et posologie , Vaccins anticholériques/effets indésirables , Vaccins anticholériques/immunologie , Méthode en double aveugle , Humains , Vaccins atténués , Vibrio cholerae/immunologieRÉSUMÉ
Vibrio cholerae El Tor strains from Peru, Bangladesh, and Bahrain were attenuated by deletion of a genetic element that encodes virulence factors and RS1. The B subunit of ctx (ctxB) was reintroduced into the recA gene of the deletion mutants, rendering them unable to recombine with exogenous genetic elements and generating Peru-3, Bang-3, and Bah-3. Fifteen volunteers received one dose of various vaccine strains at 4 x 10(6) to 1 x 10(8) cfu. All strains colonized the gut. A > or = 4-fold rise in vibriocidal titer was observed in 14 volunteers, with titers of > or = 1600 in 13. Peru-3 was the least reactogenic, but 2 of 6 volunteers had loose stools. Peru-14, a filamentous motility-deficient mutant of Peru-3, was well tolerated and colonized 18 of 21 volunteers at doses of 2 x 10(6) to 1 x 10(9) cfu. Also, when 8 Peru-3 or Peru-5 vaccinees, 5 Peru-14 vaccinees, and 8 controls were challenged with 2 x 10(6) cfu V. cholerae El Tor Inaba (N16961), 11 vaccinees were protected compared with no controls. Peru-14 shows promise as a safe, effective, single-dose oral vaccine against El Tor cholera.
Sujet(s)
Vaccins anticholériques , Choléra/prévention et contrôle , Adolescent , Adulte , Animaux , Animaux allaités , Anticorps antibactériens/sang , Vaccins anticholériques/effets indésirables , Vaccins anticholériques/génétique , Vaccins anticholériques/immunologie , Fèces/microbiologie , Femelle , Gènes bactériens/génétique , Humains , Immunoglobuline G/sang , Intestins/microbiologie , Mâle , Souris , Recombinaison génétique , Délétion de séquence , Vaccination , Vaccins atténués/effets indésirables , Vaccins atténués/génétique , Vaccins atténués/immunologie , Vibrio cholerae/génétique , Vibrio cholerae/croissance et développement , Vibrio cholerae/immunologie , Vibrio cholerae/pathogénicité , VirulenceSujet(s)
Laparoscopie , Maladies urologiques/chirurgie , Adulte , Enfant d'âge préscolaire , HumainsRÉSUMÉ
Deleting an important active-site residue of diphtheria toxin, glutamic acid-148, reduces the toxin's ADP-ribosyltransferase activity by a factor of greater than 10(4). We considered using this mutation to construct a recombinant toxoid for expression by live attenuated vaccines and explored second-site mutations that might cause reversion. Activity was partially restored by substituting glutamic acid for valine-147 or by extending the deletion by five residues toward the NH2 terminus, thereby placing glutamic acid-142 immediately adjacent to tyrosine-149. In both mutants the indicated glutamic acid may occupy a spatial locus similar to that of glutamic acid-148 in the unmutated protein. Simply deleting a crucial residue does not, therefore, provide confidence that a second-site mutation could not readily restore activity to a toxoid.
Sujet(s)
Toxine diphtérique/génétique , Séquence d'acides aminés , Sites de fixation , Toxine diphtérique/toxicité , Anatoxine diphtérique/génétique , Données de séquences moléculaires , Mutagenèse dirigée , Mutation , Poly(ADP-ribose) polymerases/génétique , Poly(ADP-ribose) polymerases/métabolisme , Conformation des protéines , Protéines recombinantes , Relation structure-activité , Vaccins synthétiques/génétiqueRÉSUMÉ
A mutant form of Pseudomonas aeruginosa exotoxin A (ETA) carrying a deletion of glutamic acid-553, an important active-site residue, was expressed in an ETA-negative strain of P. aeruginosa and shown to be exported from the cells as efficiently as wild-type ETA. The mutant protein, purified from the culture medium, was devoid of ADP-ribosyltransferase activity. Protein conformation was barely perturbed by the deletion, as determined by a number of measures, including affinity for substrate NAD, proteinase sensitivity, absorbance and fluorescence spectroscopy, and differential scanning calorimetry. The conformational integrity and stability of the mutant toxin are consistent with potential use of the protein in vaccines or as a carrier in preparing conjugate vaccines.
Sujet(s)
ADP ribose transferases , Toxines bactériennes , Exotoxines/génétique , Glutamates/génétique , Pseudomonas aeruginosa/métabolisme , Toxoïdes/génétique , Facteurs de virulence , Sites de fixation , Calorimétrie différentielle à balayage , Délétion de segment de chromosome , Électrophorèse sur gel de polyacrylamide , Endopeptidases/métabolisme , Exotoxines/isolement et purification , Acide glutamique , NAD/métabolisme , Poly(ADP-ribose) polymerases/métabolisme , Spectrométrie de fluorescence ,RÉSUMÉ
Retrospective pathologic analysis was conducted of specimens from 88 radical retropubic prostatectomy operations performed between 1982 and 1987 inclusive. The median age of patients was sixty years (range, 46 to 73 years). Of the 88 radical prostatectomies performed, 51 were nerve-sparing (40 bilateral) and 37 were nonnerve-sparing (11 unilateral) procedures. Preoperative clinical staging was similar in both groups. Thirty-five of 37 patients (95%) in nonnerve-staging group and 51 of 51 patients (100%) in nerve-sparing group had clinical Stage B2 disease or less. Pathologic staging in both groups was also similar. In 26 of 37 patients (70%) in nonnerve-sparing group and in 35 of 51 patients (69%) in nerve-sparing group, disease remained localized to the prostate. Both groups were analyzed retrospectively to determine whether or not the incidences of microinvasion of capsule and of extraprostatic disease differed. Review of the apical and lateral margins of the specimens revealed no statistically significant difference in either the degree of microinvasion of capsule or the incidence of extraprostatic disease between the groups.
Sujet(s)
Adénocarcinome/anatomopathologie , Dysfonctionnement érectile/prévention et contrôle , Prostate/anatomopathologie , Prostatectomie/méthodes , Tumeurs de la prostate/anatomopathologie , Adénocarcinome/épidémiologie , Adénocarcinome/chirurgie , Humains , Incidence , Mâle , Adulte d'âge moyen , Prostate/innervation , Tumeurs de la prostate/épidémiologie , Tumeurs de la prostate/chirurgie , Études rétrospectivesRÉSUMÉ
At the Lahey Clinic Medical Center, Double-J stents are placed primarily for management of patients with calculi. They are used before extracorporeal shock-wave lithotripsy (ESWL) of large renal calculi or bilateral ESWL treatments and after ureteroscopic instrumentation or removal of calculi. They are also used for palliative urinary diversion for patients with ureteral obstruction secondary to pelvic cancer. Fluoroscopy with C-arm guidance is the standard radiologic technique employed for manipulation of all calculi and insertion of stents. Results have been good with the use of these stents, but in 3 patients the rigid ureteroscope was required to remove a retained Double-J stent.
Sujet(s)
Endoprothèses , Uretère , Sujet âgé , Endoscopie , Femelle , Humains , Mâle , Adulte d'âge moyen , Radiographie , Uretère/imagerie diagnostiqueRÉSUMÉ
The effect of heat shock on Myxococcus xanthus was investigated during both glycerol- and starvation-induced development. Cells heat shocked at 40 degrees C for 1 h prior to a development-inducing signal displayed an accelerated rate of myxospore formation at 30 degrees C. Additionally, M. xanthus cells heat shocked prior to glycerol induction formed a greater total number of myxospores when sporulation was complete than did control cells maintained at 30 degrees C. However, in starvation-induced fruiting cells the total number of myxospores in control and heat-shocked populations was about equal when fruiting body and myxospore formation was complete. When extended heat shock (3 h) was applied to cells prior to development, no acceleration of myxospore formation was observed. Heat shock elicited the premature expression of many developmentally regulated proteins. Cell fractionation and analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography revealed the subcellular location and molecular weights of the 18 glycerol-induced and 9 starvation-induced developmental proteins. Comparison with previously identified M. xanthus heat shock proteins showed that nine of the developmental proteins found in glycerol-induced cells and three of the developmental proteins found in starvation-induced cells were heat shock proteins. Furthermore, heat shock increased the activity of alkaline phosphatase, a developmentally regulated enzyme, in vegetative cells, glycerol-induced cells, and starvation-induced cells.
Sujet(s)
Glycérol/pharmacologie , Myxococcales/physiologie , Biosynthèse des protéines , Phosphatase alcaline/métabolisme , Température élevée , Cinétique , Méthionine/métabolisme , Myxococcales/effets des médicaments et des substances chimiques , Protéines/isolement et purification , Spores bactériens/effets des médicaments et des substances chimiques , Spores bactériens/physiologieRÉSUMÉ
Fortunately, the incidence of serious bowel and conduit problems in the immediate postoperative period and within the first year after diversion is low (5 to 10 per cent). The ileal or colon conduit still serves as the standard method of urinary diversion in adults with pelvic malignancy. Prevention of these complications should truly begin in the preoperative period, and careful judgement should be used postoperatively so that no therapeutic option is undertaken too early. The goal in managing these complications is the preservation of renal function, the maintenance of longest possible amount of functioning bowel, and the absence of indwelling stents and tubes. Patience is needed, along with the maintenance of drainage, adequate nutrition, observation for and treatment of sepsis, and a careful delineation of the anatomic defects. These patients, with their high reoperative mortality rate (approximately 50 per cent), present one of the most intriguing and complicated challenges to the urologist. Using the principles outlined here, we have had only one death in 22 consecutive patients referred to the Lahey Clinic for the management of complex bowel and urinary tract complications following urinary diversion.
Sujet(s)
Maladies intestinales/étiologie , Complications postopératoires/thérapie , Dérivation urinaire/effets indésirables , Maladies urologiques/thérapie , Association thérapeutique , Humains , Iléum/chirurgie , Maladies intestinales/thérapie , Complications postopératoires/étiologie , Soins préopératoires , Réintervention , Facteurs temps , Dérivation urinaire/méthodes , Maladies urologiques/étiologieRÉSUMÉ
The heat shock response of Myxococcus xanthus was investigated and characterized. When shifted from 28 to 40 degrees C, log-phase cells rapidly ceased growth, exhibited a 50% reduction in CFU, and initiated the synthesis of heat shock proteins (HTPs). Heat-shocked log-phase M. xanthus cells labeled with [35S]methionine were found to produce 18 major HTPs. The HTPs, analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography, were characterized with regard to molecular mass, subcellular location (periplasm, membrane, or cytoplasm), and temperature required for expression. Most HTPs were expressed at 36 degrees C, the optimum growth temperature of M. xanthus. Cells preincubated at 36 degrees C for 1 h before being shifted to 40 degrees C demonstrated increased thermotolerance compared with cells shifted directly from 28 to 40 degrees C. The HTPs produced by heat-shocked starvation-induced fruiting cells and glycerol-induced sporulating cells were also analyzed and characterized. Thirteen HTPs were detected in fruiting cells shifted from 28 to 40 degrees C. Six of these HTPs were not seen in vegetative M. xanthus cells. Log-phase cells induced to sporulate by the addition of glycerol produced 17 HTPs after being shifted to 40 degrees C. These HTPs were found to be a mixture of HTPs detected in heat-shocked log-phase cells and heat-shocked fruiting cells.